NCNA NuCana plc

14.48
+0.09  (+1%)
Previous Close 14.39
Open 14.16
Price To Book 4.78
Market Cap 466777280
Shares 32,236,000
Volume 1,294
Short Ratio
Av. Daily Volume 59,380

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial to be initiated in 2019.
NUC-1031 (Acelarin)
Front-Line Treatment of Advanced Biliary Tract Cancer
Phase 1 data due 2019.
NUC-3373
Solid tumors
Phase 3 ongoing.
NUC-1031 (Acelarin)
Pancreatic cancer
Phase 2 interim data due 2019.
NUC-1031 (Acelarin)
Platinum-sensitive ovarian cancer
Phase 1 initial data due 2019.
NUC-3373
Colorectal Cancer
Phase 1 data due 2019.
NUC-7738
Solid tumors